GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexin Pharmaceuticals AB (OSTO:ANNX) » Definitions » EV-to-Revenue

Annexin Pharmaceuticals AB (OSTO:ANNX) EV-to-Revenue : (As of Jun. 20, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Annexin Pharmaceuticals AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Annexin Pharmaceuticals AB's enterprise value is kr229.84 Mil. Annexin Pharmaceuticals AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00 Mil. Therefore, Annexin Pharmaceuticals AB's EV-to-Revenue for today is .

The historical rank and industry rank for Annexin Pharmaceuticals AB's EV-to-Revenue or its related term are showing as below:

OSTO:ANNX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.565
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-20), Annexin Pharmaceuticals AB's stock price is kr0.446. Annexin Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00. Therefore, Annexin Pharmaceuticals AB's PS Ratio for today is .


Annexin Pharmaceuticals AB EV-to-Revenue Historical Data

The historical data trend for Annexin Pharmaceuticals AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexin Pharmaceuticals AB EV-to-Revenue Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - - - -

Annexin Pharmaceuticals AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Annexin Pharmaceuticals AB's EV-to-Revenue

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexin Pharmaceuticals AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's EV-to-Revenue falls into.



Annexin Pharmaceuticals AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Annexin Pharmaceuticals AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=229.839/0
=

Annexin Pharmaceuticals AB's current Enterprise Value is kr229.84 Mil.
Annexin Pharmaceuticals AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annexin Pharmaceuticals AB  (OSTO:ANNX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Annexin Pharmaceuticals AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.446/0
=

Annexin Pharmaceuticals AB's share price for today is kr0.446.
Annexin Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annexin Pharmaceuticals AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Annexin Pharmaceuticals AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Annexin Pharmaceuticals AB (OSTO:ANNX) Business Description

Traded in Other Exchanges
Address
Norrtullsgatan 6, Stockholm, SWE, SE-113 29
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.